Clinical trials: H Pylori Infection
Helicobacter Pylori Infection
Probiotics in the Reduction of Adverse Effects and Dysbiosis of H. Pylori Eradication
The investigators aimed to assess the effect of probiotic supplementation with Vigiis 101-LAB during H. pylori eradication therapy with 14-day sequential therapy in the reduction of adverse effects and the restoration of the…
- Trial name
- NCT03722433
- Testing
- Vigiis 101-LAB and sequential therapy
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori Infection, Helicobacter Pylori Infection, Susceptibility to
Eradication of H. Pylori Infection With Moxifloxacin
The main objective of the study is to compare the effectiveness of moxifloxacin triple therapy with levofloxacin-based sequential therapy in terms of eradication rate, safety, and patient compliance.
- Trial name
- RCT (NCT05863858)
- Testing
- Sequential Regimen: Levofloxacin 500 mg BID, Amoxicillin 1 gm BID, omeprazole 20 mg BID for first five days followed by Levofloxacin 500 mgBID, Tinidazole 500 mg BID, Omeprazole 20 mg BID, Triple Regimen: Moxifloxacin 400mg OD, Amoxicillin 1 gm BID, Omeprazole 20mgBID
- Where
- Pakistan
- Volunteers
- 162 people
- Sponsor
- Iyad Naeem Muhammad, PhD
Helicobacter Pylori Infection
Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)
Standard eradication therapies using proton pump inhibitors (PPIs) require double doses to achieve sufficient acid suppression, yet failure rates remain high due to antibiotic resistance.
- Trial name
- TATH-1 (NCT05647278)
- Testing
- Tegoprazan 50 mg, tablets, orally, qd, Esomeprazole 20mg BID, Tegoprazan 50 mg, tablets, orally, bid
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Zhang Xiaofeng,MD
Helicobacter Pylori Infection
Intraluminal Mono-antibiotic Therapy for Helicobacter Pylori Infection - A Comparison of Levofloxacin Powder and Levofloxacin Solution
Helicobacter pylori (H. pylori) is an important causal factor of chronic gastritis, peptic ulcer disease, gastric cancer and gastric lymphoma. The World Health Organization classified H. pylori as a Group 1 carcinogen in 1994.
- Trial name
- NCT03832465
- Testing
- Levofloxacin film-coated tablet, Levofloxacin intravenous solution
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Mackay Memorial Hospital
Dyspepsia, Chronic Gastritis
Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy
This study aims at evaluating efficacy and safety of berberine hydrochloride, amoxicillin and rabeprazole triple therapy versus bismuth-containing quadruple therapy(amoxicillin, clarithromycin, rabeprazole and bismuth) in the…
- Conditions
- Dyspepsia, Chronic Gastritis, Gastric Cancer, Helicobacter Pylori Infection
- Trial name
- NCT04697186
- Testing
- Berberine, Amoxicillin, Rabeprazole
- Where
- China
- Volunteers
- 524 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Gastric Cancer, H Pylori Infection
H. Pylori Screen-and-treat Study in a Population of Young Adults
Gastric cancer remains a major challenge to public health on a global scale. H. pylori related cancer burden contributes to the largest proportion of cancer cases attributable to infections in Europe.
- Conditions
- Gastric Cancer, H Pylori Infection, H Pylori Eradication, H-pylori
- Trial name
- NCT06275204
- Testing
- Bismuth-based quadruple therapy, Levofloxacin-based quadruple therapy, Standard triple therapy
- Where
- 7 sites in Croatia, Ireland and 4 more
- Volunteers
- 6,800 people, healthy volunteers welcome
- Sponsor
- University of Latvia
Helicobacter Pylori Infection
Effect of Propolis on Patients Infected With H. Pylori
This research aims to contribute to the literature by researching the effect of propolis as an add-on treatment and nutritional education on patients with H pylori and the alleviation of gastrointestinal symptoms.In order to…
- Trial name
- NCT05259007
- Testing
- propolis solved in lactic acid solvent, Amoxicillin-Clarithromycin-Lansoprazole, IV saline 0.9%
- Volunteers
- 96 people
- Sponsor
- Fatma Zehra Arvas
H Pylori Infection Eradication, Antibiotics Therapeutic Strategies
Therapeutic Trial Comparing Triple Therapy Guided by the PCR Detection of Clarithromycin Resistance vs Empiric Concomitant Quadruple Therapy for Helicobacter Pylori Infection
The H pylori infection remains a public health problem. The eradication rate with the first line triple therapy (PPI-amoxicillin-clarithromycin) is insufficient (estimated at 70%) due to the frequency of resistance to…
- Conditions
- H Pylori Infection Eradication, Antibiotics Therapeutic Strategies, H Pylori Eradication
- Trial name
- Hepysé (NCT02576236)
- Testing
- Quadruple concomitant therapy treatment, Triple therapy guided by the result of the molecular resistance test
- Where
- France
- Volunteers
- 2,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Gastric Cancer, Helicobacter Pylori Infection
Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population
The aim of this study is to define the role of H. pylori eradication in the prevention of gastric cancer and its precursors in the context of a population-based endoscopic screening program.
- Trial name
- HELPER (NCT02112214)
- Testing
- 10-day bismuth-based quadruple therapy
- Where
- 11 sites in South Korea
- Volunteers
- 5,224 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
Helicobacter Pylori Infection, Colorectal Cancer
European Implementation Study on Simultaneous Screening for Gastric and Colorectal Cancers
The EUGastScreen study is designed as a quality implementation study to explore gastric cancer screening strategies within organised cancer screening frameworks.
- Conditions
- Helicobacter Pylori Infection, Colorectal Cancer, Gastric Cancer
- Trial name
- EUGastScreen (NCT07873580)
- Testing
- Fecal sample acquisition for Helicobacter pylori stool antigen test, Upper endoscopy with biopsies, Colonoscopy with biopsies after bowel cleansing
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- University of Latvia
Gastrointestinal Ulcer Haemorrhage, Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Helicobacter Eradication Aspirin Trial
HEAT (Helicobacter Eradication Aspirin Trial) is a large simple double-blind placebo controlled outcomes study of Helicobacter pylori (H. pylori) eradication to prevent ulcer bleeding in aspirin users.
- Trial name
- HEAT (NCT01506986)
- Testing
- Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg
- Where
- 6 sites in United Kingdom
- Volunteers
- 30,024 people
- Sponsor
- University of Nottingham
Helicobacter Pylori Infection
Intraluminal Therapy for Helicobacter Pylori Infection
Helicobacter pylori (H. pylori) is the most common chronic bacterial infection in humans. The prevalence of H. pylori is about 30~50% in the Western adult population.
- Trial name
- NCT03124420
- Testing
- Lansoprazole, Amoxicillin, Clarithromycin
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Mackay Memorial Hospital
Helicobacter Pylori Infection, Comorbidities and Coexisting Conditions
Real-world Treatment of H. Pylori Eradication in Patients with Comorbidity
Most of the studies of H. pylori eradication were conducted in academic institutes and designed to enrolled patients who did not have comorbidities.
- Conditions
- Helicobacter Pylori Infection, Comorbidities and Coexisting Conditions, Real-world Outcome, Medication Adherence
- Trial name
- Real-world_Hp (NCT05475431)
- Testing
- The sequential therapy, The triple therapy, The hybrid therapy
- Where
- 2 sites in Taiwan
- Volunteers
- 1,053 people
- Sponsor
- National Cheng-Kung University Hospital
Suspicion of Being Infected With H.Pylori
Show Equivalence of the Modified BreathID Compared to Currently Approved BreathID in H.Pylori Detection
The purpose of this study is to confirm equivalence of a new generation breath analyzer (Modified BreathID) in its ability to detect H. pylori compared to the currently approved BreathID® System.
- Trial name
- NCT01650831
- Testing
- Modified BreathID
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Meridian Bioscience, Inc.
Helicobacter Pylori Infection
Sequential Versus Quadruple Therapy in the Second-line Treatment
Objectives: A recent randomized trial showed that 14-day sequential therapy containing high dose proton pump inhibitor was higher than 95% in the first line treatment.
- Trial name
- NCT03208426
- Testing
- Esomeprazole (S14), Esomeprazole (BQ10), Amoxicillin (ST14)
- Where
- Taiwan
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Helicobacter Infection
Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection
This study is conducted to investigate whether the efficacy of single-dose triple therapy (Esomeprazole 40 mg, Tinidazole 1 g, and Levofluxacine 500 mg) for 14 days is superior to double-dose lansoprazole 30 mg, amoxicillin 1 g…
- Trial name
- NCT02711176
- Testing
- Nexium, Tinafas, Tavanex
- Where
- Iran
- Volunteers
- 212 people
- Sponsor
- Zahra Vahdat Shariatpanahi
HELICOBACTER PYLORI INFECTIONS
Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helicobacter Pylori Eradication
With the increasing prevalence of antibiotic resistance, the clinical efficacy of conventional 7-day triple therapy for Helicobacter pylori eradication has been substantially diminished.
- Trial name
- PSM (NCT07333001)
- Testing
- 7-day triple therapy, 14-day dual therapy
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Yueyue Li
Irritable Bowel Syndrome
the Relationship Between Helicobacter Pylori Infection and Irritable Bowel Syndrome
Evaluating any possible relationship between irritable bowel syndrome occurrence and Helicobacter pylori infection
- Trial name
- NCT04847401
- Testing
- H. pylori stool antigen
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sohag University
Gastritis, Dyspepsia
Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
This study aims at evaluating efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy(esomeprazole and amoxicillin) versus bismuth-containing quadruple Therapy(bismuth，esomeprazole，tetracycline and…
- Conditions
- Gastritis, Dyspepsia, Helicobacter Pylori Infection, Gastric Cancer
- Trial name
- NCT04678492
- Testing
- Esomeprazole, Amoxicillin, Bismuth
- Where
- China
- Volunteers
- 658 people
- Sponsor
- Xijing Hospital of Digestive Diseases
H. Pylori Infection
Oral Helicobacter Pylori Eradication
Helicobacter pylori (H. pylori) is a serious health threat that infects approximately half of the global population. In addition to colonizing the stomach, H.
- Trial name
- NCT06045832
- Testing
- MAXPOWER Biological Antibacterial Liquid, Water
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Changhai Hospital